EUVIMEDExplore EUVIMED
Open access · CC BY 4.0

Fibroblast‐specific palladin drives kidney fibrosis via MRTF – SRF signaling

Naoki Yamamoto iD, Norihiko Sakai, Yuta Yamamura, Daichi Kaikoi, Daiki Hayashi, Takahiro Matsuno, Akihiko Koshino, Keisuke Sako, Keisuke Horikoshi, Takahiro Yuasa, Akira Tamai, Taichiro Minami and 16 more

The Journal of Pathology · 2026-01 · 268 (1) · 40-53

DOI: 10.1002/path.6485 ↗

At a glance

Journal article in The Journal of Pathology, published online on 2025-10-24. Written by Naoki Yamamoto and 27 co-authors. Institution: Department of Nephrology and Rheumatology, Kanazawa University, Kanazawa, Japan. Major MEDLINE topics: Fibroblasts, Serum Response Factor, Cytoskeletal Proteins, Kidney. Cited 7 times so far (Crossref); 61 references. The full text is freely available (open access, CC BY 4.0). Funded by: JSPS Grant-in-Aid for Scientific Research C, Basis for Supporting Innovative Drug Discovery and Life Science Research.

AbstractSubjectsBibliographic detailsCiteRelated studies

Abstract (original language)

Fibrosis is a common end‐stage pathway of progressive chronic kidney diseases. Previously we demonstrated that myocardin‐related transcription factor (MRTF)–serum response factor (SRF) signaling drives the expression of fibrosis‐related molecules through actin cytoskeleton dynamics in renal fibroblasts. However, it has not been elucidated whether actin‐associated proteins relate to the pathogenesis of fibrosis. Here, we reveal that the actin cytoskeleton‐regulating pathway is significantly correlated with estimated glomerular filtration rate (eGFR) and collagen type 1 alpha 1 expression in human proteome analysis. We found that palladin was one of the TGF‐β1‐dependent actin‐associated proteins in renal fibroblasts. Our mechanistic studies demonstrated that palladin activates MRTF–SRF signaling via actin cytoskeleton rearrangement upon TGF‐β1 stimulation. In addition, palladin expression itself was enhanced by MRTF–SRF signaling, indicating a positive feedback loop. In vitro , genetic silencing of the palladin–MRTF–SRF axis suppressed extracellular matrix production and myofibroblast differentiation. In preclinical models in vivo , fibroblast‐specific palladin‐deficient mice (palladin iFBKO ) were protected from kidney dysfunction and fibrosis that developed in adenine‐induced nephropathy, which was associated with reduced numbers of myofibroblasts compared to wild type (palladin F/F ) mice. In patients with renal disease, palladin was significantly upregulated in the renal interstitium of patients with low eGFR and kidney fibrosis. Moreover, upregulation of the palladin–MRTF–SRF axis correlated with kidney function and fibrosis in patients with various kidney diseases, including IgA nephropathy, diabetic nephropathy, and nephrosclerosis. Taken together, we consider palladin to be a novel regulator of actin cytoskeleton signaling in fibrotic fibroblasts and represents a novel therapeutic target for the treatment of progressive kidney diseases. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

Subjects

MeSH terms (MEDLINE)

FibroblastsSerum Response FactorCytoskeletal ProteinsKidneyPhosphoproteinsTrans-ActivatorsKidney DiseasesAnimalsHumansFibrosisSignal TransductionMiceMice, KnockoutMaleDisease Models, AnimalMice, Inbred C57BLMyofibroblastsActin CytoskeletonTransforming Growth Factor beta1

Author keywords

CKDMRTFSRFTGF‐β1actin cytoskeletonactin‐associated proteinfibroblastfibrosispalladinproteome analysis

Substances

Serum Response FactorCytoskeletal ProteinsPhosphoproteinsPALLD protein, humanTrans-ActivatorsMRTFA protein, humanMrtfa protein, mouseSRF protein, humanTransforming Growth Factor beta1

Authors and institutions

  • Department of Nephrology and Rheumatology, Kanazawa University, Kanazawa, Japan.
  • Division of Blood Purification, Kanazawa University Hospital, Kanazawa, Japan.
  • Graduate School of Veterinary Science, Azabu University, Sagamihara, Japan.
  • Laboratory of Toxicology, School of Veterinary Medicine, Azabu University, Sagamihara, Japan.
  • Division of Integrated Omics Research, Research Center for Experimental Modeling of Human Disease, Kanazawa University, Kanazawa, Japan.
  • Division of Animal Disease Model, Research Center for Experimental Modeling of Human Disease, Kanazawa University, Kanazawa, Japan.

ORCID profiles: Naoki Yamamoto

Funding

  • JSPS Grant-in-Aid for Scientific Research C
  • Basis for Supporting Innovative Drug Discovery and Life Science Research

Cite

APA

Yamamoto, N., Sakai, N., Yamamura, Y., Kaikoi, D., Hayashi, D., Matsuno, T., Koshino, A., Sako, K., Horikoshi, K., Yuasa, T., Tamai, A., Minami, T., Oshima, M., Nakagawa, S., Kitajima, S., Hara, A., Shimizu, M., Terakawa, J., Horike, S. I., …, & Iwata, Y. (2026). Fibroblast‐specific palladin drives kidney fibrosis via MRTF – SRF signaling. The Journal of Pathology, 268(1), 40-53. https://doi.org/10.1002/path.6485

Vancouver

Yamamoto N, Sakai N, Yamamura Y, Kaikoi D, Hayashi D, Matsuno T, et al. Fibroblast‐specific palladin drives kidney fibrosis via MRTF – SRF signaling. The Journal of Pathology. 2026;268(1):40-53. doi:10.1002/path.6485

BibTeX
@article{Yamamoto2026,
  author = {Yamamoto, Naoki and Sakai, Norihiko and Yamamura, Yuta and Kaikoi, Daichi and Hayashi, Daiki and Matsuno, Takahiro and Koshino, Akihiko and Sako, Keisuke and Horikoshi, Keisuke and Yuasa, Takahiro and Tamai, Akira and Minami, Taichiro and Oshima, Megumi and Nakagawa, Shiori and Kitajima, Shinji and Hara, Akinori and Shimizu, Miho and Terakawa, Jumpei and Horike, Shin-Ichi and Daikoku, Takiko and Mizokami, Atsushi and Ikeda, Hiroko and Kadoguchi, Moeno and Arakawa, Hiroshi and Ohtsuki, Sumio and Lagares, David and Wada, Takashi and Iwata, Yasunori},
  title = {Fibroblast‐specific palladin drives kidney fibrosis via MRTF – SRF signaling},
  journal = {The Journal of Pathology},
  year = {2026},
  volume = {268},
  number = {1},
  pages = {40--53},
  doi = {10.1002/path.6485}
}
Start for free →